Skip to content
10-Q

Quarterly Report

UroGen Pharma Ltd. URGN

0001437749-26-015019

← back to feed
Filed
May 6, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 48.72M sh
Capex Q1 2026 · Mar 31, 2026 $54K
Capex Q1 2026 · Mar 31, 2025 $44K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$45.32M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$42.02M
Long Term Debt Q1 2026 · Mar 31, 2026 $189.53M
Long Term Debt Q1 2026 · Dec 31, 2025 $122.21M
Short Term Investments Q1 2026 · Mar 31, 2026 $39.74M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $109.97M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $110.75M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$124.25M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$105.47M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$46.46M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$8.8M
Current Liabilities Q1 2026 · Mar 31, 2026 $50.64M
Current Liabilities Q1 2026 · Dec 31, 2025 $46.42M
Total Liabilities Q1 2026 · Mar 31, 2026 $377.94M
Total Liabilities Q1 2026 · Dec 31, 2025 $305.93M
Current Assets Q1 2026 · Mar 31, 2026 $237.46M
Current Assets Q1 2026 · Dec 31, 2025 $186.02M
Total Assets Q1 2026 · Mar 31, 2026 $253.69M
Total Assets Q1 2026 · Dec 31, 2025 $200.46M
Eps Basic Q1 2026 · Mar 31, 2026 −$0.47
Eps Basic Q1 2026 · Mar 31, 2025 −$0.92
Sga Expense Q1 2026 · Mar 31, 2026 $51.49M
Sga Expense Q1 2026 · Mar 31, 2025 $34.97M
Rd Expense Q1 2026 · Mar 31, 2026 $15.6M
Rd Expense Q1 2026 · Mar 31, 2025 $19.87M
Net Income Q1 2026 · Mar 31, 2026 −$23.57M
Net Income Q1 2026 · Mar 31, 2025 −$43.84M
Operating Income Q1 2026 · Mar 31, 2026 −$20.26M
Operating Income Q1 2026 · Mar 31, 2025 −$36.91M
Gross Profit Q1 2026 · Mar 31, 2026 $46.82M
Gross Profit Q1 2026 · Mar 31, 2025 $17.92M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $4.14M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $2.33M
Revenue Q1 2026 · Mar 31, 2026 $50.96M
Revenue Q1 2026 · Mar 31, 2025 $20.25M